ClinicalTrials.gg
Not yet recruitingNCT07949968HemodialysisUpdated Nov 20, 2026

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A Single Study in Assiut University Hospital

An observational study in End Stage Renal Disease Patients, ESRD and Renal Failure, sponsored by Shimaa Salah Ali. Not yet recruiting. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shimaa Salah Ali · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Months and older
Sex
All
01

Study summary

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A single study in Assiut university hospital

Read the detailed description

End-stage renal failure (ESRF) represents a major global health burden, with hemodialysis being the most common renal replacement therapy. The creation of an arteriovenous fistula (AVF) Is considered the preferred vascular access for long-term hemodialysis due to its superior patency and lower complication rates compared to grafts and catheters (1-2) Despite its advantages, AVF creation may be associated with several complications, including ischemic steal syndrome and ischemic monomelic neuropathy (IMN). Ischemic neuropathy is a rare but potentially disabling complication resulting from acute or chronic ischemia of peripheral nerves following AVF creation. Patients may present with severe pain, sensory disturbances, weakness, and functional impairment of the affected limb (3-5) Early diagnosis remains challenging because symptoms may overlap with uremic neuropathy, diabetic neuropathy, and other peripheral nerve disorders commonly encountered in ESRF patients. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), provide objective assessment of nerve dysfunction and may facilitate early diagnosis and differentiation from other neuropathic conditions Limited data are available regarding the electrophysiological characteristics of AVF-related ischemic neuropathy, particularly in ESRF populations. Therefore, a comprehensive electrophysiological evaluation may contribute to improved recognition, management, and prevention of long-term disability

Hemodialysis fistula-related ischemic neuropathy is an under-recognized complication in patients with ESRF. Delayed diagnosis may lead to irreversible neurological deficits and impaired quality of life. The electrophysiological features and associated risk factors remain insufficiently characterized in many dialysis populations

This study aims to provide a detailed electrophysiological assessment of ischemic neuropathy associated with AVF creation in ESRF patients. The findings may facilitate early diagnosis, improve clinical outcomes, and contribute to developing screening and management strategies for high-risk patients

Aim of the Work:

To evaluate electrophysiological abnormalities associated with hemodialysis fistula-related ischemic neuropathy in patients with end-stage renal failure

  • Primary Objective To assess peripheral nerve function using nerve conduction studies and electromyography in ESRF patients with AVF-related ischemic neuropathy
  • Secondary Objectives To compare electrophysiological findings between ESRF patients with and without ischemic neuropathy To identify clinical and vascular factors associated with the development of ischemic neuropathy To determine the severity and distribution of nerve involvement To correlate electrophysiological findings with clinical manifestations and duration of AVF use

Patients and methods:

Type of the study: Analytical Cross-Sectional Case-Control Study Study Setting: The study will be conducted at Nephrology and Hemodialysis Unit at Assuit University hospital

Study duration: august 2026 - august 2027 Study populations: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy Inclusion Criteria Age ≥18 years Diagnosed ESRF on regular hemodialysis Exclusion Criteria Pre-existing hereditary neuropathies Cervical radiculopathy Brachial plexopathy Motor neuron disease. Recent upper limb trauma. Peripheral nerve entrapment syndromes. Severe cognitive impairment. Refusal to participate

Methodology A. Clinical Assessment

All participants will undergo:

Detailed medical history, Dialysis history

AVF characteristics:

Site of fistula Duration since creation Side of fistula Previous vascular interventions

Neurological examination:

Motor assessment Sensory assessment Deep tendon reflexes Muscle strength grading using MRC scale B. Laboratory Investigations Complete blood count (CBC) Serum creatinine Blood urea nitrogen (BUN) Electrolytes HbA1c (for diabetic patients) Serum albumin Calcium and phosphorus levels C. Vascular Assessment Duplex Doppler ultrasonography of AVF Assessment of arterial flow and steal phenomenon D. Electrophysiological Assessment

Nerve Conduction Studies (NCS):

Electromyography (EMG)

02

Conditions studied

  • End Stage Renal Disease Patients
  • ESRD
  • Renal Failure

Keywords

  • Hemodialysis
  • Electrophysiological Study
  • End-Stage Renal Failure
  • Fistula-Related Ischemic Neuropathy
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 276 are open to participants now.

This study's planned enrollment of 50 is below the median of 120 across 444 observational studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

This is the only study on the registry with Shimaa Salah Ali as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosed ESRF on regular hemodialysis

Exclusion criteria

Exclusion Criteria:

  • Pre-existing hereditary neuropathies
  • Cervical radiculopathy
  • Brachial plexopathy
  • Motor neuron disease.
  • Recent upper limb trauma.
  • Peripheral nerve entrapment syndromes.
  • Severe cognitive impairment.
  • Refusal to participate
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Motor Nerve Conduction Velocity

    Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second.

    Time frame: Up to 1 year post-AVF creation

  2. Arteriovenous Fistula Blood Flow Volume

    Assessed by Duplex Doppler Ultrasound on the arteriovenous fistula. Measured in milliliters per minute.

    Time frame: Up to 1 year post-AVF creation

Secondary outcomes

  1. Sensory Nerve Conduction Velocity

    Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second

    Time frame: Up to 1 year post-AVF creation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2028, 13 months later.

Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 13 months is below that.

Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 20, 2026
StartEst.
Nov 4, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949968
Lead sponsor
Shimaa Salah Ali
Collaborators
Assiut University
Responsible party
Shimaa Salah Ali (Assistant lecturer, Assiut University) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Nov 4, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion